Second Risperdal Gynecomastia Trial Concludes in Pennsylvania
A Pennsylvania juryconvened to weigh evidence in the trial of an important Risperdal lawsuit ruled on Friday that the antipsychotic medication did not cause the plaintiff’s excessive breast growth. However, the panel did agree with the lawsuit’s assertion that Johnson & Johnson and its Janssen Pharmaceuticals unit failed to warn that Risperdal could cause gynecomastia (male breast development) in men and boys.
While the jury did not award the plaintiff any damages, his attorneys indicated to Reuters that they still considered the outcome an overall victory for Risperdal gynecomastia plaintiffs. After all, this marks the second time in a month that a jury hearing a Risperdal bellwether case has faulted the drug’s makers for failing to warn about its potential to cause the condition.
Nearly 1,300 Risperdal Claims Pending in Pennsylvania
According to court documents, the case that concluded last week is just one of nearly 1,300 Risperdal lawsuits pending in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, all of which accuse Johnson & Johnson and Janssen of concealing information about gynecomastia and other serious complications associated with its use. The plaintiff at the center of the latest bellwether trial took Risperdal as a child on an on-and-off basis until 2007 to treat oppositional defiant disorder. At the time, the drug hadn’t been approved for any pediatric uses.
Bellwether trials are used in large, consolidated proceedings such as the Risperdal mass tort to test the strength of plaintiff’s claims in cases involving similar allegations of fact. The outcomes of such trials in Pennsylvania could provide clues as to jury rulings in Risperdal lawsuits that put forth similar gynecomastia allegations.
Pennsylvania’s first bellwether trial of a Risperdal gynecomastia lawsuit concluded on February 24th, with the jury awarding $2.5 million in compensatory damages to a man who was prescribed the drug as a child to treat symptoms associated with autism. As a result, he developed size 44 DD breasts during puberty. Court documents pending in Philadelphia indicate that a number of other cases involving gynecomastia will head to trial in the Risperdal litigation later this year.
Learn More about Filing a Risperdal Gynecomastia Claim
The Risperdal lawyers at Bernstein Liebhard LLP are actively filing gynecomastia claims in the Pennsylvania litigation. If you or someone you care about experienced excessive male breast development that might be linked to Risperdal, please call (877) 779-1414 for your free, no-obligation legal review.